文献速递腹部CT

灌注CT——胃癌中一种新型定量与定性影像生物标志物

Perfusion CT - A novel quantitative and qualitative imaging biomarker in gastric cancer.
PubMed 文献 · Eur J Radiol · 2017-09-21

研究纳入24例经活检或临床证实的胃癌患者,在新辅助治疗前后行64排CT灌注扫描,评估血流量、血容量、平均通过时间和表面通透性。肿瘤缩小≥25%与血流量和表面通透性显著相关,治疗有效者血流量、血容量和表面通透性下降而平均通过时间延长。作者认为灌注CT可无创评估肿瘤血管新生并早期识别治疗反应者。

要点

  • 胃癌新辅助治疗前较高的血流量和表面通透性提示治疗更有效。
  • 治疗有效者灌注参数表现为血流量、血容量和表面通透性下降、平均通过时间延长。
  • 血容量和平均通过时间与肿瘤缩小无显著相关。

核心结论

  • 灌注CT可无创评估胃癌活体血管新生,有助于早期识别治疗反应者和无反应者。
  • 作者认为作为标准流程,治疗反应的完整评估应包括评估血管新生的灌注CT检查。

研究设计与样本

  • 研究纳入24例活检阳性或临床证实的胃癌患者,均行灌注CT检查。
  • 16例接受化疗,8例接受放化疗。
  • 使用64排GE断层扫描仪,基于去卷积模型的首过灌注方案,于基线和新辅助治疗后行灌注CT检查。

关键影像表现/征象

  • 灌注CT评估参数包括血流量、血容量、平均通过时间和表面通透性。
  • 新辅助治疗后肿瘤缩小与血流量和表面通透性显著相关。
  • 血容量和平均通过时间与肿瘤缩小无显著关系。
  • 治疗反应阳性者血流量、血容量和表面通透性下降,平均通过时间延长。

诊断标准与关键数值

  • 新辅助治疗(化疗和放化疗)临床反应阳性定义为肿瘤缩小25%或以上。

临床应用与阅片要点

  • 原文结论认为灌注CT可作为标准流程中评估治疗反应的一部分,包括评估血管新生。
  • 原文未据此给出具体的阅片或报告操作推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: The aim of this research was to examine whether Perfusion Computed Tomography (P-CT) can qualitatively and quantitatively help detect gastric cancer neoangiogenesis in vivo as well as treatment response evaluation. We attempted to explore which P-CT parameters are best used in neoangiogenesis and neoadjuvant therapy for most effective evaluation. We also tried to recognize a positive prediction value of P-CT in early responders and non-responders patients identification.

MATERIALS AND METHODS: Twenty-four patients with positive biopsy results and/or clinically proven gastric cancer were enrolled in the P-CT exam. Patients were qualified for systemic treatment (16 patients received chemotherapy and 8 patients received radiochemotherapy). The baseline Perfusion-CT exam and after neoadjuvant treatment Perfusion-CT exam were conducted using a 64-row GE tomograph based on a deconvolution model in first-pass protocol perfusion. The P-CT examined the following parameters: Blood Flow (BF), Blood Volume (BV), Mean Transit Time (MTT) and Permeability Surface (PS). Positive clinical response to neoadjuvant treatment (CHT and RCT) was defined as tumor size reduction 25% or more.

RESULTS: Tumor dimension reduction after neoadjuvant therapy was significantly correlated with the BF and the PS. Neoadjuvant therapy was more effective for patients with higher output BF and PS values. We did not register a significant relationship between BV and MTT parameters and tumor dimension reduction. Patients with a positive treatment response showed a decrease in BF, BV and PS perfusion parameters with an increase in MTT.

CONCLUSIONS: P-CT examination allows a noninvasive neoangiogenesis assessment in vivo, leading to early identification of responding and non-responding patients. As a standard procedure, a full evaluation of treatment response should include a P-CT exam assessing neoangiogenesis.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Kruk-Bachonko J, Krupski W, Czechowski M, et al. Perfusion CT - A novel quantitative and qualitative imaging biomarker in gastric cancer. Eur J Radiol. 2017. PMID: 28987697. doi:10.1016/j.ejrad.2017.08.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。